This transfer reprogrammed TAMs from anti‐tumor CD5L+ to pro‐tumor TREM2+ phenotypes, increasing CCL18 secretion, reducing phagocytic activity, and impairing CD8+ T cell proliferation. The gene discussed is CD5L; the disease is neoplasm.